Why The Coming Months Could Be A “Biotech Bonanza”

“It was a difficult first half for biotech stocks, once again underscoring how conditions may seem so ideal but investment returns can still be hard to generate,” notes the author of today’s article. When it comes to the second half of the year, however, he expects that exposure to biotech stocks will be much more rewarding. For more on this potential “biotech bonanza” – and some promising biotech companies to watch – CLICK HERE.